Risk & Volatility Yubo International Biotech has a beta of 3.09, meaning that its share price is 209% more volatile than the S&P 500. Comparatively, Yubo International Biotech’s competitors have a beta of 0.
96, meaning that their average share price is 4% less volatile than the S&P 500. Institutional and Insider Ownership 44.3% of shares of all “Electromedical equipment” companies are held by institutional investors.
56.5% of Yubo International Biotech shares are held by insiders. Comparatively, 15.
3% of shares of all “Electromedical equipment” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Profitability This table compares Yubo International Biotech and its competitors’ net margins, return on equity and return on assets.
Earnings and Valuation Yubo International Biotech’s competitors have higher revenue and earnings than Yubo International Biotech. Yubo International Biotech is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry. Summary Yubo International Biotech competitors beat Yubo International Biotech on 5 of the 9 factors compared.
About Yubo International Biotech ( Get Free Report ) Yubo International Biotech Limited, through its subsidiaries, focuses on the research and development, and application of endometrial stem cells. It offers healthcare products for respiratory system, skincare products, hair care products, healthy beverages, and male and female personal care products; and stem cell related services, including cell testing and health management consulting services under the VIVCELL brand. The company is headquartered in Beijing, China.
Receive News & Ratings for Yubo International Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Yubo International Biotech and related companies with MarketBeat.com's FREE daily email newsletter ..
Business
Financial Contrast: Yubo International Biotech (YBGJ) & Its Rivals
Risk & Volatility Yubo International Biotech has a beta of 3.09, meaning that its share price is 209% more volatile than the S&P 500. Comparatively, Yubo International Biotech’s competitors have a beta of 0.96, meaning that their average share price is 4% less volatile than the S&P 500. Institutional and Insider Ownership 44.3% of shares [...]